Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01163682 · ClinicalTrials.gov registry record · NA

Electro-acupuncture for the Prevention of Taxane Induced Myalgias and Neuropathy

A NA study of Breast Cancer and Neuropathy, sponsored by Columbia University.

Completed
Registry status
NA
Development phase
63
Enrollment target
1
Study location

NCT01163682: Completed NA study of Breast Cancer and Neuropathy, sponsored by Columbia University.

NCT01163682 is a NA study of Breast Cancer and Neuropathy that has completed, run by Columbia University. The registered enrollment target is 63 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01163682, a NA study of Breast Cancer and Neuropathy, has completed, sponsored by Columbia University.

COMPLETED
Registry status
NA
Development phase
63 participants
Enrollment target
1
Study location

Study Summary

This study seeks to determine if 12 weeks of weekly electro-acupuncture will prevent or decrease neuropathic pain in breast cancer patients receiving 12 weekly treatments of taxane treatment.

Primary Outcome

The change in neuropathic pain, as measured by the mean Brief Pain Inventory-Short Form (BPI-SF) worst pain score, from baseline to 16 weeks, in the study group that received electro-acupuncture (intervention), was compared to the change in neuropathic pain in the study group that received sham acupuncture (control). Scores range from 0 (no pain)-10 (worst pain) with a higher score indicating worse outcome.

Conditions Studied

Interventions

  • DEVICE Electro-acupuncture
  • DEVICE Sham acupuncture

Study Locations (1)

New York

  • Columbia University Medical Center - New York

Trial Details

FieldValue
Enrollment Target 63 participants
Start Date 2010-12
Est. Completion 2017-05
Phase NA
Columbia University

958 total trials

What the finished NCT01163682 record still lists

NCT01163682 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 63 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower).

The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Electro-acupuncture is the first listed.

NCT01163682 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT01163682 about?

NCT01163682 is a clinical study titled "Electro-acupuncture for the Prevention of Taxane Induced Myalgias and Neuropathy". This study seeks to determine if 12 weeks of weekly electro-acupuncture will prevent or decrease neuropathic pain in breast cancer patients receiving 12 weekly treatments of taxane treatment.

What is the current status of trial NCT01163682?

This trial is currently completed. It is a NA study. The enrollment target is 63 participants. The study started on 2010-12. Estimated completion is 2017-05.

What conditions does trial NCT01163682 study?

This clinical trial studies the following conditions: Breast Cancer, Neuropathy.

What interventions are being tested in trial NCT01163682?

The interventions under investigation include: Electro-acupuncture (DEVICE), Sham acupuncture (DEVICE).

Who is sponsoring clinical trial NCT01163682?

This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01163682 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01163682's enrollment target sits among peer trials

63 727th of 1224 higher than 495 of 1,224 other Breast Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03383575 · 63 participants · Phase 2

    Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome

  • NCT04870944 · 63 participants · Phase 1

    CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

  • NCT05031897 · 63 participants · Phase 2

    Two Step Haplo With Radiation Conditioning

  • NCT05312671 · 63 participants · Phase 2

    Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01163682, the US trial registry maintained by the National Library of Medicine. NCT01163682 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.